AF
DAWN

Abound Financial’s Day One Biopharmaceuticals DAWN Stock Holding History

Abound Financial’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.01K Hold
327
– – ﹤0.01% 223
2025
Q4 		$3.05K Buy
+327
New +$2.73K ﹤0.01% 246
2025
Q2 		– Sell
-327
Closed -$2.59K – 113
2025
Q1 		$2.59K Buy
+327
New +$3.52K ﹤0.01% 242

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Abound Financial's DAWN Position: Q1 2026 in Review

Abound Financial held its Day One Biopharmaceuticals (DAWN) position steady in Q1 2026 at 327 shares worth $7.01K. The position accounts for ﹤0.01% of the portfolio, ranked #223.

Abound Financial first reported a position in DAWN in Q1 2025 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Abound Financial held 327 shares of Day One Biopharmaceuticals worth $7.01K as of Q1 2026.
  • Abound Financial left its Day One Biopharmaceuticals share count unchanged in Q1 2026.
  • Day One Biopharmaceuticals made up ﹤0.01% of Abound Financial's portfolio in Q1 2026, its #223 holding.
  • Abound Financial first reported a position in Day One Biopharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Abound Financial's 13F filing for Q1 2026, filed 4 May 2026.